3 completed, 1 terminated. 3 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Diva De Leon: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia Exendin-(9-39), Vehicle - Postprandial Hypoglycemia | Not applicable | Completed | Diva De Leon | 7 | 2010-04-01 | 2017-10-23 |
| Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia Exendin (9-39), Vehicle - Congenital Hyperinsulinism | Phase 1 / Phase 2 | Terminated | Diva De Leon | 14 | 2009-08-26 | 2020-06-01 |
| Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity Exendin-(9-39), placebo - Congenital Hyperinsulinism | Phase 1 / Phase 2 | Completed | Diva De Leon | 17 | 2009-05-01 | 2020-03-13 |
| Effect of Exendin-(9-39) on Glycemic Control in Subjects With Congenital Hyperinsulinism Exendin-(9-39), Vehicle - Congenital Hyperinsulinism | Phase 1 / Phase 2 | Completed | Diva De Leon | 9 | 2007-08-01 | 2017-12-11 |
Hypoglycemia (4) · Congenital Hyperinsulinism (3) · Hyperinsulinism (3) · Glucose Metabolism Disorders (1) · Infant, Newborn, Diseases (1) · Metabolic Diseases (1) · Pancreatic Diseases (1)
exendin (9-39) (4) · Saline Solution (2)
United States (4)
Diva D De Leon, MD (1) · Diva D De Leon, MD MSCE (1) · Diva D DeLeon, MD (1)
R03DK078535 (1)